Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It
Debate At CTAD Underscores Doctors’ Dilemma
The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.
